![ESMO-Webinar-Breast-Cancer-1000x250](/var/esmo/storage/images/media/esmo/meetings/2022/_webinars/esmo-webinar-breast-cancer-1000x250/11099510-2-eng-GB/esmo-webinar-breast-cancer-1000x250_i770.jpg)
Login to get immediate access to this content.
LoginESMO Members take the CME test
and receive 1 ESMO - MORA point
Learning objectives
- To increase knowledge on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2- breast cancer
- To provide up to date information on the value of CDK4/6 inhibitors in adjuvant management of these patients as well as highlight ongoing research
- To emphasise the value of multidisciplinary assessment of patients with early breast cancer in the personalised medicine era